ANLN and cancer: Innovatively, we developed a prognostic risk model using LASSO and Cox regression on three hub genes (WDR72, ANLN, SLC16A12), integrating multi-omics data for immune microenvironment, tumor mutation burden (TMB), cancer stem cell (CSC) index, and drug sensitivity assessment.